Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.31%) hit a four-year low Monday, falling below $44 a share in early trading, a level the stock hasn't seen since July 2021. What's ...

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...